Regenerative Financing MAPS/ Vine SPV

About

MAPS is formed as a non-profit and public benefits corporation and is in Phase 3 clinical trials for MDMA for PTSD. MAPS expects to have approval from the FDA by 2023. As a non-profit, MAPS cannot receive equity financing. Thus, this SPV was set up to provide investors with revenue share payments based on North America sales of MDMA for use in MDMA-assisted therapy.